Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 17/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.63 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.63 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217449 | 0.92 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL15298823 | 0.88 | RAF1 (0.81) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3226554 | 0.84 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10220677 | 0.78 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3213560 | 0.77 | MAPK14 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3216740 | 0.77 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3245607 | 0.76 | MAPK14 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10220054 | 0.76 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3217350 | 0.74 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3244244 | 0.74 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296811-B2 | Methods for treating a tumor using an antibody that specifically binds HMW-MAA | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296811-B2 | Methods for treating a tumor using an antibody that specifically binds HMW-MAA | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140234324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-08-21 | — | — | US | disclosed |
| US-8771687-B2 | Methods for treating a tumor using an antibody that specifically binds GRP94 | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771687-B2 | Methods for treating a tumor using an antibody that specifically binds GRP94 | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130259873-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS HMW-MAA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2013-10-03 | — | — | US | disclosed |
| US-20130259873-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS HMW-MAA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2013-10-03 | — | — | US | disclosed |
| US-20120178780-A1 | RAF KINASE INHIBITORS | WOOD JILL E (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178780-A1 | RAF KINASE INHIBITORS | WOOD JILL E (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120148598-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-06-14 | — | — | US | disclosed |
| US-20100063088-A1 | Raf Kinase Inhibitors | WOOD JILL E | 2010-03-11 | — | — | US | disclosed |
| US-20100063088-A1 | Raf Kinase Inhibitors | WOOD JILL E | 2010-03-11 | — | — | US | disclosed |
| EP-0986382-B1 | RAF KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20050256174-A1 | Raf kinase inhibitors | BAYER HEALTHCARE LLC | 2005-11-17 | — | — | US | disclosed |
| US-20010006975-A1 | Raf kinase inhibitors | BAYER CORPORATION AND ONYX PHARMACEUTICALS WEST HAVEN, CT AND RICHMOND, CA, RESPECTIVELY | 2001-07-05 | — | — | US | disclosed |
| US-6187799-B1 | TREATING CANCEROUS CELL GROWTH MEDIATED BY RAF KINASE BY ADMINISTERING SPECIFIED COMPOUNDS, SUCH AS 2-(METHYOXYCARBONYL),3-((4-METHYLPHENYL)UREA),5-ALKYL-THIOPHENE | ONYX PHARMACEUTICALS | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063088-A1 | Raf Kinase Inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885MAPK14 239/4885MAPK13 150/4885 |
| US-20130259873-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS HMW-MAA | PA2G4, BRAF, HSPA1A | RAF1 107/4885MAPK14 2287/4885MAPK13 2788/4885 |
| US-20120148598-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | LY96, HSPA2, BRAF | RAF1 77/4885MAPK14 1605/4885MAPK13 1939/4885 |
| US-20140234324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | LY96, HSPA2, BRAF | RAF1 77/4885MAPK14 1605/4885MAPK13 1939/4885 |
| US-20050256174-A1 | Raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885MAPK14 239/4885MAPK13 150/4885 |
| US-20120178780-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885MAPK14 239/4885MAPK13 150/4885 |
| US-20010006975-A1 | Raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885MAPK14 239/4885MAPK13 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.